NeoStem and ImmuneRegen BioSciences have announced a collaborative research agreement, which focuses on the development of an advanced, adult human stem cell product.
Under the agreement, NeoStem will investigate the effects of Homspera, ImmuneRegen’s lead drug candidate, which, when used with NeoStem’s VSEL(TM) technology, has been shown to enhance stem cell activity.
ImmuneRegen’s Homspera has previously been shown to affect the differentiation of human adult stem cells, particularly into hematopoietic stem cells that are capable of becoming blood cells.
Under the collaboration, NeoStem has the right to execute an option agreement to negotiate an exclusive licence to resulting technology.
NeoStem is pursuing the research and development of adult stem cell therapies, both in the US and China, from small embryonic-like stem cells, which represents a significant step towards overcoming the ethical limitations in the development of stem cell therapies.